EG433182 Inhibitors
EG433182 inhibitors are a chemical class of compounds that specifically target the EG433182 protein or related molecular pathways. Structurally, these inhibitors often contain a core scaffold with heterocyclic moieties that allow for high specificity and binding affinity to their target proteins. The variations in their substituent groups contribute to different binding kinetics, solubility, and metabolic stability, making the structure-activity relationship (SAR) of EG433182 inhibitors a key area of focus for chemical optimization. Many compounds in this class contain functional groups that interact with the active or allosteric sites of the target protein, forming hydrogen bonds, hydrophobic interactions, or van der Waals forces that enhance binding stability. The flexibility and modular nature of their chemical structures allow for significant tuning to achieve desired physicochemical properties, such as improved lipophilicity, permeability, and binding selectivity.
From a biochemical perspective, EG433182 inhibitors play a critical role in modulating enzymatic activities or protein-protein interactions associated with the EG433182 pathway. By binding to their target protein, these inhibitors can either block the protein's active site, preventing substrate access, or alter the protein's conformation, thereby affecting its function. The fine-tuning of these interactions is achieved through modifications in their chemical structure, which can significantly impact binding affinity and specificity. Moreover, these inhibitors are often designed to be selective to avoid off-target effects and to maintain stability within a biological environment. The molecular design and synthesis of EG433182 inhibitors emphasize the balance between potency and chemical properties like solubility and bioavailability, ensuring the compounds are effective under physiological conditions. Overall, this class of inhibitors is characterized by its precision in molecular targeting and adaptability through chemical modifications, making them a significant focus in biochemical research for understanding EG433182-related pathways and molecular mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose inhibits glycolysis by acting as a glucose analog and competitively inhibiting hexokinase. This disruption of the glycolytic pathway may indirectly inhibit Eno1b, affecting its enzymatic activity and potentially impacting cellular processes dependent on glycolytic flux. | ||||||
Lonidamine | 50264-69-2 | sc-203115 sc-203115A | 5 mg 25 mg | $105.00 $364.00 | 7 | |
Lonidamine disrupts hexokinase activity and inhibits ATP production. By affecting glycolysis, it may indirectly inhibit Eno1b, impacting its role in energy metabolism. The decreased energy availability may influence cellular processes dependent on Eno1b function. | ||||||
Oxamic acid | 471-47-6 | sc-250620 | 25 g | $148.00 | ||
Oxamic Acid is a competitive inhibitor of lactate dehydrogenase, affecting the conversion of pyruvate to lactate. This inhibition may indirectly influence Eno1b, as it modulates the balance between glycolysis and lactate production, potentially altering the metabolic context in which Eno1b operates. | ||||||
Phosphoglycolic Acid | 13147-57-4 | sc-477531 | 10 mg | $485.00 | 2 | |
Phosphoglycolic Acid interferes with glycolysis by inhibiting enolase activity. Given its direct impact on the same enzymatic family as Eno1b, this compound directly inhibits Eno1b function, disrupting the conversion of 2-phosphoglycerate to phosphoenolpyruvate and potentially affecting downstream cellular processes. | ||||||
Dichloroacetic acid | 79-43-6 | sc-214877 sc-214877A | 25 g 100 g | $61.00 $128.00 | 5 | |
Dichloroacetic Acid inhibits pyruvate dehydrogenase kinase, indirectly promoting the activity of pyruvate dehydrogenase. This may impact Eno1b indirectly by altering the availability of pyruvate, a metabolite interconnected with glycolysis, affecting the metabolic context in which Eno1b functions. | ||||||
6-Aminonicotinamide | 329-89-5 | sc-278446 sc-278446A | 1 g 5 g | $156.00 $398.00 | 3 | |
6-AN is a selective inhibitor of 6-phosphogluconate dehydrogenase, a key enzyme in the pentose phosphate pathway. By affecting an alternative metabolic pathway, it may indirectly influence Eno1b by altering the availability of metabolites that intersect with glycolysis, impacting the cellular context in which Eno1b operates. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin inhibits thioredoxin reductase, disrupting cellular redox balance. Indirectly, this disruption may influence Eno1b, as redox status is intricately connected to glycolysis. Changes in redox potential may impact Eno1b's enzymatic activity and potentially affect cellular processes dependent on glycolytic metabolism. | ||||||
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $64.00 $255.00 | 13 | |
Phloretin inhibits glucose transporters, reducing glucose uptake. By limiting substrate availability for glycolysis, it may indirectly impact Eno1b, influencing its role in energy metabolism. The altered metabolic state may affect cellular processes in which Eno1b is involved. | ||||||